絞り込み

16647

広告

「"Crittenden DB "[Author]」の検索結果

25件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.

Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome.

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.

A Model for Assessing the Clinical and Economic Benefits of Bone-Forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-Term Risk of Osteoporotic Fracture.

Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking.

Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures.

Greater Gains in Spine and Hip Strength for Romosozumab Compared to Teriparatide in Postmenopausal Women With Low Bone Mass.

A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care.

Unmasking romosozumab: response to commentsby Uzoigwe et al.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data.

Hyperuricemia, Gout, and Related Comorbidities: Cause and Effect on a Two-Way Street.

The crystallization of monosodium urate.

The year in gout: 2012-2013 - a walk through the 2012 ACR Gout Treatment Guidelines.

New therapies for gout.

  1. 1
  2. 2
Sort by
※並べ替えは表示に時間がかかります